AACR Annual Meeting 2026

April 17–22, 2026 · San Diego · 2418 items

← Breast cancer: HER2 de-escalation, MRD, TNBC

#BCSM

1 person · 2 posts

Other cases in this chapter

T-DXd + pertuzumabPFS HR 0.56; ILD ~12%, including 2 grade 5
zanidatamabNo-chemo neoadjuvant pCR 30%
pumitamigTNBC cORR 61.5%
NSABP-B-59ctDNA predicted non-pCR and distant recurrence

Floor

Apr 21Tue

Tuesday · 2 items

07:31
OncLive.com@OncLiveScore6060
WATCH: Marija Balic, MD, PhD, discusses the potential role of tumor-informed ctDNA testing in early triple-negative breast cancer based o...
Same topic #BCSM · 1 personHeat 11 like0 replies0 reposts
05:30
OncLive.com@OncLiveScore6060
Molecular testing identified actionable alterations in high proportions of patients with breast and colorectal cancers, regardless of ctD...
Same topic #BCSM · 1 person #CRCSMHeat 00 likes0 replies0 reposts